Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
meeting symbols : Alks save search
Alkermes Shareholders Re-Elect All Seven Company Director Nominees at 2023 Annual General Meeting of Shareholders
Published: 2023-06-29 (Crawled : 15:20) - investor.alkermes.com
ALKS | $23.78 -0.96% -0.97% 1.8M
|
Health Technology
|
| O: -0.37%
H: 1.08%
C: -3.72%
meeting
Alkermes Announces Two Abstracts Accepted for Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2023-05-09 (Crawled : 11:00) - investor.alkermes.com
ALKS | $23.78 -0.96% -0.97% 1.8M
|
Health Technology
|
| O: 0.19%
H: 1.16%
C: -0.16%
presentation meeting
Alkermes Announces Results of Annual General Meeting of Shareholders
Published: 2022-07-07 (Crawled : 21:00) - prnewswire.com
ALKS | $23.78 -0.96% -0.97% 1.8M
|
Health Technology
|
| O: -0.6%
H: 2.33%
C: 1.79%
meeting results
Alkermes Presents ARTISTRY-1 Data at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-06-01 (Crawled : 12:20) - biospace.com/
ALKS | $23.78 -0.96% -0.97% 1.8M
|
Health Technology
|
| O: -0.03%
H: 0.0%
C: 0.0%
Alkermes Announces Four Abstracts Accepted for Presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2022-05-09 (Crawled : 12:00) - investor.alkermes.com
ALKS | $23.78 -0.96% -0.97% 1.8M
|
Health Technology
|
| O: -2.44%
H: 1.73%
C: -2.06%
presentation
Alkermes to Present Data on Nemvaleukin Alfa at the Society of Gynecologic Oncology 2022 Annual Meeting on Women's Cancer
Published: 2022-03-01 (Crawled : 16:20) - investor.alkermes.com
ALKS | $23.78 -0.96% -0.97% 1.8M
|
Health Technology
|
| O: -0.4%
H: 1.53%
C: -3.35%
nemvaleukin women cancer
Alkermes to Present Data on Nemvaleukin Alfa at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
Published: 2021-11-03 (Crawled : 12:15) - biospace.com/
ALKS | $23.78 -0.96% -0.97% 1.8M
|
Health Technology
|
| O: -2.41%
H: 3.58%
C: 3.48%
immunotherapy therapy cancer nemvaleukin
Alkermes Presents New Data on Nemvaleukin Alfa at 2021 American Society of Clinical Oncology Annual Meeting
Published: 2021-06-04 (Crawled : 13:15) - investor.alkermes.com
ALKS | $23.78 -0.96% -0.97% 1.8M
|
Health Technology
|
| O: 0.69%
H: 0.43%
C: -0.65%
nemvaleukin
Alkermes to Host Webcast With Expert Oncologist Panel to Discuss Data on Nemvaleukin Alfa Presented at 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
Published: 2021-05-28 (Crawled : 20:00) - investor.alkermes.com
ALKS | $23.78 -0.96% -0.97% 1.8M
|
Health Technology
| Email alert
Add to watchlist
nemvaleukin
Alkermes Announces Two Abstracts Accepted for Presentation at 2021 American Society of Clinical Oncology Annual Meeting
Published: 2021-04-28 (Crawled : 11:00) - investor.alkermes.com
ALKS | $23.78 -0.96% -0.97% 1.8M
|
Health Technology
|
| O: -2.22%
H: 2.68%
C: -1.05%
presentation
Alkermes Announces Posting of Briefing Documents for FDA Advisory Committee Meeting on ALKS 3831
Published: 2020-10-07 (Crawled : 10:21) - investor.alkermes.com
ALKS | $23.78 -0.96% -0.97% 1.8M
|
Health Technology
|
| O: 0.63%
H: 6.28%
C: 5.35%
fda
Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 35th Anniversary Annual Meeting
Published: 2020-11-09 (Crawled : 10:21) - investor.alkermes.com
ALKS | $23.78 -0.96% -0.97% 1.8M
|
Health Technology
|
| O: 0.47%
H: 6.32%
C: 4.86%
cancer therapy immunotherapy
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.